Hair-loss drug coverage sparks debate over national health insurance priorities

President Lee Jae Myung, then the presidential candidate of the Democratic Party of Korea, brushes back his hair while explaining his campaign pledge to extend national health insurance coverage to hair-loss medication in a YouTube video for the 2022 presidential campaign. Captured from YouTube

The Korean government's plan to extend National Health Insurance Service (NHIS) coverage to hair-loss medication is drawing mounting criticism from patient groups and medical experts, who argue that it could undermine the core principles of the public health insurance system.

Critics question whether subsidizing hair-loss treatment should take priority over expanding coverage for life-saving therapies for patients with severe illnesses. They also warn that approving coverage for hair-loss drugs could open the door to similar demands for weight-loss medications, growth hormone treatments and other therapies that fall somewhere between medical necessity and quality-of-life improvement.

According to government officials on Thursday, the Ministry of Health and Welfare will hold a public discussion on July 4 as part of the interior ministry's "Forum for Everyone" initiative to gather public opinion on the proposal. The ministry is considering expanding insurance coverage beyond conditions such as alopecia areata to include androgenetic alopecia — the common hereditary form of hair loss known in Korea as M-shaped baldness.

The issue gained political momentum after President Lee Jae Myung described hair loss as "a matter of survival" during a ministry briefing late last year and urged officials to examine insurance coverage.

Health Minister Jung Eun-kyung initially opposed the idea, arguing that hair loss "does not threaten life or health" and that cosmetic concerns have traditionally fallen outside the scope of NHIS benefits. However, after repeated calls from the president, the ministry shifted toward reviewing the proposal.

Officials say President Lee ordered further public consultation in February after receiving both supporting and opposing arguments from the ministry. While some government insiders viewed the ministry's presentation of opposing views as a subtle attempt to express reservations, critics argue that the ministry has instead failed in its role as guardian of the health insurance system.

Health Minister Jung Eun-kyung speaks at a forum in Seoul, May 13. Yonhap

Patient advocacy organizations and medical professionals argue that covering hair-loss drugs would violate the fundamental principle of public health insurance by diverting limited resources away from patients with serious illnesses.

The Korea Federation for Severe Disease Patients criticized the proposal as "a populist policy that undermines the foundation of the NHIS, whose purpose is to protect people from catastrophic medical costs caused by serious illness."

The group added that while patients with rare diseases and terminal cancers are becoming "medical poor" because they cannot afford expensive treatments, extending insurance benefits to hair-loss medication would effectively leave critically ill patients behind.

Experts also warn that once hair-loss medication is covered, patients seeking insurance support for anti-obesity drugs, growth hormone therapy, and other treatments could make similar claims by arguing that their conditions also affect quality of life — or even survival. Such demands could place additional strain on Korea's health insurance finances.

Although the NHIS reserve fund reached a record 30.2 trillion won ($22 billion) last year, government projections show it could be depleted by 2033 due to rapidly rising medical costs associated with population aging.

Additional spending commitments — including paid sick leave benefits, insurance coverage for long-term care hospital caregivers, and the proposed hair-loss drug subsidies— could accelerate that timetable.

Medical experts estimate that covering hair-loss medication alone would cost at least 100 billion won ($73 million) annually.

"Once you abandon medical necessity as the standard for insurance coverage, policy priorities risk being driven by whichever interest groups have the loudest voices," said Jeong Jae-hoon, a professor of preventive medicine at Korea University College of Medicine. "Hair loss may indeed be deeply distressing for some people, but decisions on how to spend limited insurance resources should be based on clear principles and evidence."

The issue has also become politically divisive.

Rep. Kim Mi-ae of the opposition People Power Party criticized the government, saying healthcare policy "should not be approached through populism."

Meanwhile, Rep. Kim Won-i of the ruling Democratic Party of Korea, who has advocated insurance coverage for hair-loss treatment since 2020, defended the proposal, saying it would help young people who face disadvantages in employment, dating and marriage because of hair loss. "I want to give them hope," he wrote on Facebook.

This article from the Hankook Ilbo, the sister publication of The Korea Times, is translated by a generative AI system and edited by The Korea Times.